Elevated TWIST1 expression in myelodysplastic syndromes/acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine

Hongjiao Li; Yi Wang; Xingchen Pang; Chenglian Xie; Joachim H Deeg; Hui Wang; Ting Wan; Jinpeng Wu; Feng Guan; Xiang Li

doi:10.3324/haematol.2019.235325

Elevated TWIST1 expression in myelodysplastic syndromes/acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine

Haematologica. 2020 Oct 1;105(10):e502. doi: 10.3324/haematol.2019.235325.

Authors

Hongjiao Li¹, Yi Wang², Xingchen Pang³, Chenglian Xie¹, Joachim H Deeg⁴, Hui Wang², Ting Wan⁵, Jinpeng Wu¹, Feng Guan¹, Xiang Li¹

Affiliations

¹ Key Laboratory of Resource Biology and Biotechnology Western China, Northwest University,Xi'an,China.
² Department of Hematology, Provincial People Hospital, Xian, Shaanxi, China.
³ School of Biotechnology, Jiangnan University, Wuxi, China.
⁴ Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, USA.
⁵ Wuxi School of Medicine, Jiangnan University, Wuxi, China.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Azacitidine / therapeutic use
Decitabine / therapeutic use
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Myelodysplastic Syndromes* / drug therapy
Myelodysplastic Syndromes* / genetics
Nuclear Proteins / genetics
Twist-Related Protein 1

Substances

Nuclear Proteins
TWIST1 protein, human
Twist-Related Protein 1
Decitabine
Azacitidine

Grants and funding

Funding: the present study was supported by the National Natural Science Foundation of China (No. 81770123), the 13115 Key Projects of Scientific and Technical Innovation of Shaanxi Province (2010ZDKG-53), and Hundred-Talent Program of Shaanxi Province, and Youth Innovation Team of Shaanxi Universities.